Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it priced its initial public offering of 20,000,000 Class A ordinary shares at $10.00 per share. The shares are ...

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a research report issued to clients and investors on Monday, ...

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Supernus (SUPN) with an Overweight rating and $57 price target Supernus has ...

Evolv Technology Holdings, a leader in AI-based weapons detection, faces ongoing regulatory hurdles, making its current stock ...

As we enter the new year, cryptocurrency has been enjoying a thriving environment, with every angle turning out in its favor.

December, two jubilant groups came together to celebrate their recent, interconnected turns in fortune: the freewheeling ...

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...

Wall Street is glued to Donald J. Trump’s every move as he steps back into the White House, ready to disrupt, change, and ...

The Securities and Exchange Commission (SEC) on Thursday charged Cantor Fitzgerald L.P., a global financial services firm ...

Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to investors on Thursday, December 26th. HC Wainwright ...

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports.

The European Union is stumbling in its attempt to regulate the crypto market while Trump’s America accelerates ahead. With the EU’s Markets in Cryptoassets (MiCA) regulation set to take full effect by ...